
















FIG. 2








FIG. 5A





FIG. 5B



U
S
G
L





FIG. 5D



உயிர்




FIG. 6A

Cohort 6a ADA Response Values and Titer




FIG. 6B




FIG. 7A




FIG. 7B




FIG. 8B




FIG. 8A




FIG. 8D

FIG. 8C




FIG. 8E

Parameter	Cohort 7	Cohort A	Cohort B	Cohort C	Cohort D
Cmax (ng/mL)	5.7	8.8	11.8	14.7	24.5
Tmax (days)	49.3	49.2	49.2	49.2	49.2
Cmin* (ng/mL)	0.80	1.22	1.62	2.04	3.37
AUC** (ng*day/mL)	92.7	179.4	239.2	308.5	466.3

FIG. 9A

*Cmin: trough concentrations prior to Cmax
**Calculated for D1-D56 (through Cycle 2)

Cohort	Cmax:Cmin* at Cmax	ACU:Cmax	Highest Cmax:Cmin in Cycle 1	
			Dose	Dose Cmax:Cmin*
Cohort 7	7.07	16.3	C1D22	9.54
Cohort A	7.26	20.4	C1D22	6.76
Cohort B	7.26	20.3	C1D22	6.75
Cohort C	7.23	21.0	C1D22	6.42
Cohort D	7.29	19.0	C1D22	7.18

FIG. 9B

*Cmin: C1 Cmin prior to C1 Cmax




FIG. 10




FIG. 11

FIG. 12




FIG. 13A

Patient Characteristics										Treatment and Outcomes									
Patient ID	Cohort	TR1130 Dose (µg/kg)	TR1130 Dose (flat dose, µg/week)	Age/Sex/Race	WHO Classification	Previous Therapies (Number, Venetoclax and/or Decitabine)	Percent Myeloblasts	Karyotype/Mutations	CRS (Grade)	Grade 3-5 AE	SAE	Neurotoxicity	DLT	Best Overall Response	Time to Progression (days)	Time to Death or Hospice	Survival Status at last FU		
UPN01	6B	0.1	12	76/M/ C	AML with MDS-rf	1; Venetoclax +Decitabine	29	7,del(5q)/TP53 NF1	No	No	No	Insomnia (G1), CID11, 18d	No	CR	288	>352	A		
UPN02	6B	0.2	12	58/F/C	AML with MDS-rf	2; Venetoclax + Decitabine	6	7,del(5q),del(17p)/TP53	No	No	No	None	No	PD	38	122	D		
UPN03	6A	0.2	18	65/F/C	AML with recurrent genetic abn.	4; Venetoclax + AZA	40	inv(16)/ND	No	No	No	No	No	SD/RES	NA	75	D		
UPN04	6B	0.3	12	40/F/C	AML with MDS-rf-gene mutations	8; Venetoclax +Decitabine	29	t(1;15)(5;10) 11q23/FLT3-ITD	No	No	No	No	No	PD	49	97	D		
UPN05	6A	0.4	18	73/F/C	AML- NOS/MO	2; Venetoclax + AZA	15	46, XX, del(20)(q11.2q13.1)/ND	C6D17 (G1,2d)	Sepsis(3), Diarrhea(3), Vomiting(3) (C6D15, 5d)	Sepsis(3), Diarrhea(3), Vomiting(3) (C6D15, 5d)	Dizziness (1), Lethargy(1), C8D15-22	No	SD	288	>395	A		
UPN06	7	0.4	24	78/F/C	AML with MDS-rf	4; AZA	78	46,XX/None	C5D1 (G2,2d)	Confusion (G3,C1D1,1d) No	C5D1 (G2 CRS,2d)	Confusion (G3,C1D1,1d)	PBBC-C+ >50% BLR-BM	SD+	211	282	D		
UPN07	10	0.7	60	47/M/ B	AML with mutated RUNX1	3; Decitabine	4	t(2;15)/ NF1,RUNX1, GATA2,IKZF1	No	No	No	No	No	SD	>106	>110	A		
UPN08	10	0.7	60	82/M/ C	AML with gene mutations	2; Venetoclax + AZA	50	-Y/FLT3-ITD	No	No	No	No	No	SD/RES	>117	>124	A		

FIG. 13B

Patient ID ^s	Cohort	APVO 436 Dose (mcg/kg)	APVO 436 Dose (mcg/weeks)	Age/Sex/Race	WHO Classification	IPSS Prognosis Score (Risk Group)	Karyotype	Previous Therapies (Number: HMA or Venetoclax + HMA)	CRS(Grade)	Grade 3-5 AE	SAE	Neurotoxicity	DLT	Percent Myeloblasts- PRE	Percent Myeloblasts- POST	Best Overall Response	Time to Progression (Days)	Time to Death or Hospice (Days)	Survival Status at last FU
UPN09	4	0.1	9	77/F/C	MDS-EB-1	1.5(IM-2)	Intermediate	1: Decitabine	No	>3*	No	No	No	8	4(C10D22)	SD	321	330	D
UPN10	6A	0.2	18	80/M/C	MDS-EB-1	1.0(IM-1)	Good	1: AZA	No	No	No	No	No	7.5	2.4(C2D1)	Marrow CR - SD	138	138	D
UPN11	7	0.3	24	75/M/C	MDS-EB-2	2.5(High)	Intermediate	3: Decitabine	No	No	No	No	No	11.3	0(C2D1)	Marrow CR - SD	104	138	D
UPN12	9	0.4	48	75/M/C	MDS-EB-1	0.5(IM-1)	Good	1: AZA	No	No	No	No	No	8.2	2(C2D1)	Marrow CR - SD	147	>167	A
UPN13	8	0.5	36	69/M/A	MDS-EB-1	2.0(IM-2)	Poor	2: Venetoclax AZA	C2D1 (G1)	No	No	No	No	5	5(C2D1)	SD	211	>232	A
UPN14	10	0.8	60	74/F/C	MDS-EB-1	1.5(IM-2)	Intermediate	1: AZA	No	No	No	No	No	6	6(C3D1)	SD	>78	>78	A

FIG. 14

UPN	Clinical Response	IFN- γ (pg/mL)		IL-5 (pg/mL)		IL-10 (pg/mL)	
		Predose	Post C2D1	Predose	Post C2D1	Predose	Post C2D1
UPN01(AML)	PR—CR	16.7 (0.4)	34.7** (1.3)-E 10.0 (1.9)-L	0.4 (0.08)	0.6 (0.1)-E 0.2 (0.05)L	0.2 (0.04)	0.3 (0.05)-E 9.2* (0.3)-L
UPN05(AML)	SD	5.0 (0.7)	9.0 (2.6)-E 9.7** (1.3)-L	-	-	0.4 (0.08)	0.4 (0.01)-E 3.3* = 0.2-L
UPN06(AML)	PBBC-C	2.9 (-)	3.5 (0.5)	5.4 (0.2)	10.4*** (4.3)-E 7.5 (0.2)-L	0.7 (0.02)	1.7 (0.07)-E 12.1* (0.7)-L
UPN09(MDS)	SD	350.2 (4.1)	130.6 (12.2)	0.1	0.2	7.1 (0.2)	1.7 $\pm$ 0.2
UPN10(MDS)	Marrow CR	3.4 (1.3)	3.1 (-)	1.4 (0.03)	1.1 (0.07) 0.4 (0.05)	0.4 (0.05)	0.3 (0.01)-E 9.8* (0.3)-L
UPN13(MDS)	SD	2.6 (-)	-	0.4 (0.05)	0.6 (0.03)	0.8 (0.03)	0.7 (0.03)

UPN	Putative CD123 ⁺ LSC CD123 ⁺ CD34 ⁺ CD38 ⁻ Number (% of CD45+)/% Depletion	Putative CD33 ⁺ LSC CD33 ⁺ CD34 ⁺ CD38 ⁻ Number (% of CD45+)/ % Depletion	CD45 ⁺
UPN01/AML			
Baseline/C1D1	155 (0.16%)	156 (0.17%)	94,415
C2D15	74 / 52.3%	73 / 53.2%	86,266
C4D1	717 54.2%	72 / 53.8%	89848
C6D1	37 (0.04%) / 76.1%	36 (0.04%) / 76.9%	84,337
UPN03/AML			
Baseline/C1D1	2757 (2.8%)	2732 (2.8%)	97928
EOT/C1D30	1163 (1.2%) / 57.8%	1153 (1.2%) / 57.8%	93827
UPN05/AML			
Baseline/C1D1	13782 (15.4%)	13147 (14.7%)	99598
C2D15	21115 / 0%	17185 / 0%	94131
C4D1	22787 / 0%	18565 / 0%	96053
C6D1	23653 (=24.3% of CD45+) / 0%	15001 (=15.4% of CD45+) / 0%	97346
UPN06/AML			
Baseline/C1D1	1569 (1.7%)	1552 (1.7%)	92694
C2D15	24 / 98.5%	23 / 98.5%	92219
C4D1	12 (0.01%) / 99.2%	12 (0.01%) / 99.2%	92694
C6D1	33 (=0.01% of CD45+) / 97.9%	32 (=0.01% of CD45+) / 97.9%	93863
UPN09/MDS			
Baseline/C1D1	1441 (1.52%)	907 (0.96%)	94715
C2D1	1489 / 0%	1191 / 0%	94300
C4D1	947 / 34.3%	575 / 36.6%	95129
C6D1	1419 / 4.7%	1421 / 0%	94893
UPN10/MDS			
Baseline/C1D1	833 (0.9%)	836 (0.9%)	972155
C2D15	833 / 0%	775 / 7.3%	101335
C4D1	477 (0.48%) / 42.7%	457 / 45.8%	99979
EOT/C5D20	2567 (2.5%) / 3.1-fold expansion)	2296 (2.3%) / 2.7-fold expansion	100884

UPN03 had 40% bone marrow blasts at screening and also 40% at C1D22. EOT was on C1D30.

UPN10 has 7.5% bone marrow blasts at screening and 20% bone marrow blasts on C5D1. EOT was on C5D20.

FIG. 15